Pulmonary Rehabilitation in IPF

Condition: Idiopathic pulmonary fibrosis

Eligibility

Key Inclusion Criteria

  • Currently taking nitendanib for 3-18 months
  • At least 40 years old at time of screening 

Full Study Name

Study of Pulmonary Rehabilitation in Nintedanib Treated Patients With IPF: Improvements in Activity, Exercise Endurance Time and QoL (IRB no. 55418)   

Summary
The purpose of this study is to examine pulmonary rehabilitation in individuals with idiopathic pulmonary fibrosis (IPF) who are taking a medication called Ofev (nintedanib). The study aims to determine whether pulmonary rehabilitation improves the physical activities and quality of life in these patients. Pulmonary rehabilitation (PR) is a program that may include exercise, education and support to help improve the health of individuals with breathing diseases.

Specifically, the study will determine the difference in change from baseline assessment when PR is added to stable underlying Ofev therapy in patients with IPF; evaluate the difference in quality of life when PR is added to stable underlying Ofev therapy; and determine whether PR has an enduring effect when added to stable underlying Ofev therapy.

Participants will be randomly assigned to one of two study groups. The first group will receive pulmonary rehabilitation several times a week for 12 weeks at the Cedars-Sinai Pulmonary Rehabilitation Program; the second group will not receive pulmonary rehabilitation. All participants will continue to take Ofev as prescribed. 

Phase
Phase IV

Principal Investigator

Sara Ghandehari, MD

Contact
Niree Hindoyan
Phone: 310-423-4788
Email: niree.hindoyan@cshs.org